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Herein, we report a continuous-flow process for the preparation of triazenes, whereby diazonium salts are generated
and converted into their masked or protected triazene derivatives. Key to realizing the process, which is applicable to a
wide range of substrates, is the identification of solvent and reagent parameters that avoid fouling and clogging in the
tubing used in these studies. The process has also been applied to prepare the antineoplastic agents mitozolomide and
dacarbazine. We also report isolation and differential scanning calorimetry (DSC) analysis of an anthranilic acid-
derived triazene whose related diazonium salt is a contact explosive. The data highlights improved stability but also
suggests that an exothermic process does occur with an onset temperature of 118 °C. Finally, an 18-hour continuous
operation of the reaction procedure using high-performance liquid chromatography (HPLC) pumps is reported.
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1. Introduction
AQ3AQ4 Chemical functional groups containing nitrogen are ubiquitous
across the physical and biological sciences. Indeed, nitrogen and
the amine functional group in particular are present in a large
number of products from commercial suppliers of fine chemicals.
However, it is notable that there are still very few methods for the
activation and use of a C–N bond as a tool for the construction of
more complex molecules, with the formation and use of diazo-
and diazonium compounds being the most widely adopted proc-
ess to achieve this goal [1]. However, there are several drawbacks
to the use of diazonium compounds, not the least of which include
the associated safety hazards that are well documented particu-
larly with isolating these intermediates [2]. Unsurprisingly then,
the formation and use of diazo- and diazonium compounds have
been well explored under continuous-flow conditions, and indeed,
this research continues to produce exciting results and is clearly a
rich seam which will be further explored [3, 4]. An alternative
method for the safe handling of diazonium compounds is to trap
them as their more stable and protected triazene forms by reaction
with a secondary amine (SchemeS1 1) [5].
AQ5 Triazenes themselves are an exciting class of compounds dis-
playing much of the reactivity of diazonium salts, but in recent
years, they are also being demonstrated to direct catalytic or
stoichiometric metalation reactions [6, 7]. Under acidic condi-
tions, triazenes exist in equilibrium with their diazonium conge-
ners; thus, their use as a protecting group is reversible to unveil the
latent reactivity of a diazonium compound. Thus, triazenes can be
converted to the corresponding azides by treatment with a Lewis
acid and TMSN3 (SchemeS2 2) [6a]. Alternatively, the diazonium
can be unveiled and then participate in palladium coupling chem-
istries such as Sonogashira, Suzuki, and amino-carbonylation
reactions — with all of these processes occurring in one-pot
operations from the triazene material [6b–e]. Traditional Sand-
meyer chemistry can be conducted using the appropriate copper
salt with addition of acid[6f]. The Balz–Schiemann fluorination
reaction is also applicable where treatment with HBF4 provides
the desired transformation [6g]. With regards to directing metal-
ation reactions, triazenes have been successfully used to guide
ortho-deprotonation using sec- or tert-butyllithium (SchemeS3 3). In
the former case, carbon dioxide was used as a quench, leading
indirectly to anthranilic acid-derived triazenes, whereas, in the
latter case, the lithium was transmetalated to magnesium and then
added to a cyclobutanone intermediate on the way towards the
synthesis of welwitindolinone A isonitrile [7a]. AQ6More recently,
Hafner and Bräse demonstrated that a silver-mediated trifluoro-
methylation reaction was directed to the ortho position by the
triazene handle [7b], while Huang showed that Rh (III) can be
Scheme 1. Preparation of triazenes from diazonium compounds
Scheme 2. Examples of the conversion of triazenes to other functional
groups
* Author for correspondence: DLBrowne@cardiff.ac.uk
DOI: 10.1556/1846.2016.00025 J. Flow Chem.
© 2016 Akadémiai Kiadó
Full Paper
used to catalyze C–H olefination reactions ortho to a triazene
directing group [7c].
Therefore, the most exciting facet of the triazene functional
group is the combination of these properties, whereby they can
be installed starting from a wide variety of commercially avail-
able anilines and then used to direct controlled and selective
catalytic C–H functionalization processes before being removed
under acidic conditions to participate in diazonium type reac-
tivity. Owing to this, they have been classified as a “functiona-
lizable or modifiable directing group” [8].
Continuous-flow processing is suited for the preparation of
hazardous intermediates such as diazonium compounds because
they can be made and consumed within the same reactor series
[9]. Thus, the total of hazardous material at any one point in
time is very small. It is equal to the volume of the “hot-section”
(“hot” being used to describe the section of tubing between the
formation and consumption of the hazardous material) multi-
plied by the concentration. If the reactor is operating under
segmented flow conditions where the segment volume is less
than that of the “hot volume,” the volume of hazardous material
is just determined by the volume of the segment. In any case,
the total volume of hazardous material is small. In batch mode,
however, the quantity of hazardous material per unit time is
directly related to the bulk reaction volume. At scale, therefore,
the bulk preparation of a hazardous and potential explosive
intermediate is a huge risk that could be mitigated by conduct-
ing the reaction under continuous conditions. While triazenes
are protected forms of diazonium salts, they are most commonly
accessed through a batch-wise preparation of the diazonium
followed by quenching with a secondary amine; thus, the haz-
ard still exists and has the opportunity to present itself during
the process. We were therefore interested in establishing a
multistep flow process [10] for the in situ diazotization of
amines and subsequent trapping as a triazene functionality that
could then be further manipulated or stored.
2. Results and Discussion
2.1. Initial Setup. From the outset, we were mindful that one
of the key challenges for establishing a flow process for this
chemistry would be identifying optimal solvent combination
ratios to avoid precipitation and fouling of the tubular reactors
[11]. This was especially true as there are some reports that
highlight the possibility for diazonium salts to precipitate and
behave as contact explosives [2a]. Specifically, a survey of the
literature methods for the batch preparation of triazenes high-
lighted a common factor of the use of a mineral base in combi-
nation with the basic secondary amine of interest [6, 7]. The
mineral base (such as K2CO3) is typically added to neutralize
the acidic conditions necessary for the diazonium forming reac-
tion with the amine and then present solely as a reactant to
feature in the product. The mineral base is therefore sacrificial
in nature. As shown in Scheme S44, our initial setup consequently
consisted of the merging of five streams to a common flow line
to effect two reactions: first, the diazotization of the aniline by
combining with an acid and a nitrite followed by passage
through a small cooled reaction coil (Scheme 4, zone A) and,
second, neutralizing this with a sacrificial base and merging
with the required amine and passing through another reaction
coil (Scheme 4, zone B) to form a triazene. It was found that the
use of isoamyl nitrite rather than sodium nitrite meant that
acetonitrile instead of water could be incorporated as a solvent
within our reactor and keep materials in solution (Scheme 4 cf.
entries 1 and 2). We then explored the behavior in zone B and
found that the addition of an aqueous solution of a mineral base
(K2CO3) leads to rapid precipitation at the T-piece due to
insolubility in the diluted organic solvent. We conducted some
observational batch experiments to identify conditions that
would lead to homogenous mixtures yet still afford good con-
version (using 19F nuclear magnetic resonance (NMR) as a
conversion guide). It was found that the use of Et3N as base
avoided precipitate formation but also resulted in complex
Scheme 3. Examples of the use of triazenes to direct metalation
reactions
Scheme 4. Initial reactor setup and optimization of conditions
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mixtures as observed by 19F NMR of the crude reaction mate-
rial. Conversely, both dimethylaminopurine (DMAP) and piper-
idine provided positive results in both homogeneity and NMR
analysis. Therefore, piperidine was chosen as both the sacrifi-
cial base and the amine nucleophile and, thus, delivered via a
single pump in a total of 4.5 equivalents. Under continuous
conditions, this afforded a 48% isolated yield of the triazene
product without any solids formation (2). The sub-optimal yield
in this particular case is due to a competing nucleophilic aro-
matic substitution reaction where the triazene is acting as a
para-electron-withdrawing group to the fluorine leaving group
with a piperidine nucleophile.
2.2. Aniline Scope. With these conditions in hand, the setup
was used next to investigate the scope of the process with
respect to aniline — paying particular attention to problems
associated with fouling or clogging arising from covering a
cross-section of substrates (SchemeS5 5). Initially, it was found
that the para-chloroaniline underwent the continuous process
without incident, and indeed, in this case, an improved yield of
95% (1) was isolated, supporting the notion of a competing
SNAr process for the fluoro derivative. It was found that a range
of halogen bearing anilines all proceeded in good isolated yield
without incident in the reactor, including ortho-, meta-, and
para-bromo-anilines (5, 6, and 7). Notably, the workup of the
products is very straightforward with a simple liquid–liquid
extraction affording products that were typically greater than
90% purity. para-Nitro aniline did not proceed as straightfor-
wardly as other examples, also likely arising from SNAr type
reactivity but, this time, with N2 gas as the leaving group of the
diazonium intermediate. Indeed, outgassing, leading to seg-
ments of gas and liquid, was visible in this example. However,
an isolated yield of 72% of the desired triazene (4) could be
achieved following column chromatography.
Most notably, the triazene of anthranilic acid (8) was directly
made using flow conditions. The diazonium salt of which is
known to lose nitrogen and carbon dioxide gas to generate
benzyne in situ which can react exothermically if adequate
temperature control is not provided. During the course of this
work, we have been unable to find experimental literature
evidence as to the stability of triazenes compared to diazonium
counterparts. Much literature cites that these materials are sta-
ble, and we have not found reports of them being explosive.
While a lack of data suggests that they are inherently more
stable (literature is available on this topic for diazonium salts),
it does not afford hard evidence. We therefore decided to run
differential scanning calorimetry (DSC) of the anthranilic acid-
derived triazene (8). This material was found to be readily
isolated with a workup procedure following that of the other
triazene examples prepared. The DSC data (Scheme S66) show
that this triazene has an endothermic phase transition (melting)
with an onset temperature of 84 °C; this is followed by a
strongly exothermic process that is 10 times bigger than the
melting phase change with an onset temperature of 118 °C.
Notably, this exotherm is broad in shape and heating does not
accelerate which signifies that this is not a runaway or sudden
energy release.
This data fully supports the notion that triazenes are more
stable than diazonium salts, but one should demonstrate caution
if heating the neat solid materials.
We also used our reactor system to prepare the antineoplastic
compound dacarbazine, which features on the World Health
Organization (WHO) model list of essential medicines [12].
Dacarbazine is active against metastatic melanoma by a DNA
alkylatingmode of action [13]. Here, it was prepared starting from
the requisite amino imidazole and using a solution of dimethyl-
amine in THF as the secondary amine nucleophile (Scheme 5). By
delivering the amine in a changed solvent system, this may have
had a knock-on effect on the isolation of the product which is also
more aqueous soluble than the other materials prepared; nonethe-
less, dacarbazine was isolated in 47% yield.
Scheme 5. Reaction scope with respect to aniline component
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2.3. Secondary Amine Scope. Next, the scope with respect
to secondary amine was explored, again, paying attention to any
precipitate or fouling of the tubes across a variety of substrates.
In addition to piperidine, it was also found that pyrrolidine (11),
morpholine (12), diisopropylamine (13), and dimethylamine
(15) were functional in the flow process without precipitate
formation (SchemeS7 7). The resulting products were all formed
in good to excellent yields. In addition, we have prepared the S-
proline-methylester-derived triazene (14) in 90% isolated yield
(Scheme 7). It is noteworthy that all triazenes reported here
exhibit restricted rotation type behavior. This leads to temper-
ature-dependent coalescence. Importantly, for the default room
temperature 13C NMR spectra of these compounds, the signals
corresponding to the alpha carbons to nitrogen (of the amine
component) are extremely broad and not readily discernible
from the baseline. This appears to be congruent with supporting
data files in other literature that concerns the preparation of
triazenes but is not mentioned or noted as a general observation
or phenomena [14]. We are actively exploring the rotation
barriers and variable temperature NMR behavior of these mate-
rials. In addition to this, the signals of the attached protons also
appear unexpectedly broad and do not show the expected (any)
coupling patterns in the 1H NMR spectra (see electronic Sup-
porting Information for a brief account of this). X-ray crystal-
lography has been used to verify and confirm the prepared
material as a triazene, and variable temperature studies of the
same molecule show a coalescence effect.
In addition to intermolecular examples, we also briefly
explored intramolecular triazene formation where the amine
component is tethered to the formed diazonium (Scheme S88).
Indeed, treatment of N-phenyl-o-phenylenediamine to the flow
reactor system furnished the benzotriazole product (16) in
excellent isolated yield [15]. It was at this juncture that we were
also able to prepare the antineoplastic agent mitozolomide (17)
[16]. Treatment of the previously used dacarbazine aminoimi-
dazole with the appropriate alkylisocyanate furnished the start-
ing material for the flow reactor process. Application of this
Scheme 6. Differential scanning calorimetry plot of the anthranilic acid-derived triazene
Scheme 7. Reaction scope with respect to secondary amine component
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material to the flow conditions provided mitozolomide in 53%
isolated yield. Again, in this instance, we suspect that the
isolated yield is relatively low due to partition coefficients
during the workup phase.
2.4. Large-Scale Experiment. Finally, we were mindful
that, until now, the triazene materials had been prepared on
relatively small scales (1–2 mmol) due to the use of single-shot
syringe pumps delivering the reagents to the reactor in relatively
low concentrations (these were necessary to avoid precipitation).
We therefore switched our reactor setup to incorporate the use of
high-performance liquid chromatography (HPLC) pumps that
could continually process directly from solvent reservoir bottles.
Our setup is shown in SchemeS9 9 and comprises of four 2-piston
HPLC pumps, the reactor coils, and solvent reservoirs. We chose
4-bromoaniline and piperidine as the substrates for this process
demonstration. In the event, the material was processed continu-
ously for 18 h without fouling or clogging of the reactor. In the
normal fashion, low dilution leads then to a bottleneck in the
downstream processing of the product solution which becomes
laborious, unless an inline workup method is incorporated [17].
For the first hour of processing, the sample was collected and
extracted in the usual batch-way to afford 92% isolated yield of
the desired product (5). We proceeded to “spot-check” at time
points beyond this and analyzed material by NMR spectroscopy.
This highlighted that the pump flow rates deviated from the
desired set point and, thus, led to less pure samples and drew
our attention to the issues such as low reagent levels, pump
priming, and back-washing of the pumps to get the process back
on track and within the defined specification.
3. Conclusion
In summary, we have reported a continuous-flow process for
the preparation of triazenes with the in situ generation and
consumption of diazonium salts. Key to realizing a process
was the identification of solvent and reagent parameters that
would avoid fouling and clogging in the 0.8-mm ID tubing used
in these studies. The process has also been applied to a wide
range of substrates and the preparation of intramolecular exam-
ples including the antineoplastic mitozolomide and the dime-
thylamine intermolecular adduct dacarbazine. We also report
isolation and DSC analysis of an anthranilic acid-derived tri-
azene whose related diazonium salt is a contact explosive high-
lighting improved stability. Finally, we demonstrated an 18-
hour continuous operation of the reaction procedure using
HPLC pumps to deliver the material.
Scheme 8. Intramolecular triazene examples including mitozolomide
Scheme 9. Setup for continuous experiment using HPLC pumps in place of single-shot syringe systems
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4. Experimental
4.1. General Methods. All reagents and solvents were com-
mercially available and were used without further purification if
not stated otherwise. Petroleum ether refers to the 40–60 °C
fraction.
For the measurement of 1H, 13C, and 19F NMR spectra, a
Bruker Fourier300 (300 MHz), 400 UltraShield™ (400 MHz), or
Ascend™ 500 (500 MHz) was used. The obtained chemical
shifts δ are reported in ppm and are referenced to the residual
solvent signal or to the standard trifluorotoluene (−63.72 ppm)
in 19F NMR. Spin–spin coupling constants J are given in Hz.
13C spectra are reported as obtained at default temperature
(room temperature about 18 °C).
The flow setup consisted of perfluoroalkoxy (PFA) tubing of
0.8 mm ID and two pumps. The residence coils were made from
the tubing by taking the appropriate length for the desired volume.
Column chromatography was performed using 60 A (40–64 μm)
silica and solvent mixtures of petroleum ether and ethyl acetate or
dichloromethane.
High resolution mass spectral (HRMS) data were obtained on
a Waters MALDI-TOF mx at Cardiff University or on a Thermo
Scientific LTQ Orbitrap XL by the EPSRC UK National Mass
Spectrometry Facility at Swansea University.
Infrared (IR) spectra were obtained from a Shimadzu IR-
Affinity-1S FTIR and melting points using a Gallenkamp appa-
ratus and are reported uncorrected.
DSC measurements were performed using a TA instruments
Q100. The sample was heated to 160 °C from 40 °C using a 5 °
C/min gradient.
References to spectroscopic data are given for known
compounds.
4.2. General Method for the Preparation of Triazenes
1–10 in Flow (Scheme 5). Solutions of the aniline (0.2 M in
acetonitrile), HCl (0.6 M in water), isoamylnitrite (0.2 M in
acetonitrile), and piperidine (0.9 M in acetonitrile) were pre-
pared. These were then pumped through the flow system (see
Scheme 5) at a flow rate of 0.2 mL/min. After reaching steady
state (20 min), 20 mL (1 mmol, 25 min) was collected. The
reaction solution was neutralized with aqueous NaHCO3,
extracted with EtOAc (3 × 20 mL), washed with brine, and
dried over MgSO4. After removing the solvent under reduced
pressure, the crude product was taken up in CH2Cl2 and filtered
through a plug of silica. If the purity of the product did not
exceed 90%, the crude product was further purified by column
chromatography.
•AQ7 1-((4-Chlorophenyl)diazenyl)piperidine (1) [6 h]: 1H
NMR (400 MHz, CDCl3) δ 7.32–7.27 (m, 2H), 7.24–
7.19 (m, 2H), 3.77–3.63 (m, 4H), 1.71–1.54 (m, 6H). 13C
NMR (101 MHz, CDCl3) δ 149.5, 131.0, 129.0, 122.0,
25.5, 24.5.
• 1-((4-Fluorophenyl)diazenyl)piperidine (2) [18]: 1H
NMR (500 MHz, CDCl3) δ 7.43–7.37 (m, 1H), 7.05–
6.98 (m, 1H), 3.81–3.69 (m, 2H), 1.77–1.64 (m, 3H). 13C
NMR (126 MHz, CDCl3) δ 162.0, 160.0, 147.5 (d, J =
2.9 Hz), 129.0, 122.0 (d, J = 8.1 Hz), 116.5, 115.5 (d, J =
22.4 Hz), 48.5, 25.5, 24.5. 19F NMR (376 MHz, CDCl3)
δ -119.01 (s, 1F).
• 1-((4-Methylphenyl)diazenyl)piperidine (3) [6h]: 1H
NMR (400 MHz, CDCl3) δ 7.36–7.30 (m, 2H), 7.17–
7.10 (m, 2H), 3.81–3.67 (m, 4H), 2.34 (s, 4H), 1.79–1.61
(m, 6H). HRMS (EI+): [C12H17N3] calc. 203.1422,
found 203.1423.
• 1-((4-Nitrophenyl)diazenyl)piperidine (4) [6h]: 1H NMR
(500 MHz, CDCl3) δ 8.24–8.14 (m, 1H), 7.54–7.46 (m,
1H), 4.03–3.73 (m, 2H), 1.93–1.58 (m, 3H). 13C NMR
(126 MHz, CDCl3) δ 156.0, 145.0, 125.0, 120.5, 53.5,
44.0, 26.5, 24.5, 24.5.
• 1-((4-Bromophenyl)diazenyl)piperidine (5) [14]: 1H
NMR (400 MHz, CDCl3) δ 7.43 (d, J = 8.8 Hz, 1H),
7.30 (d, J = 8.8 Hz, 1H), 3.77 (d, J = 5.6 Hz, 2H), 1.70 (d,
J = 1.6 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 150.0,
132.0, 122.0, 118.5, 25.5, 24.5.
• 1-((3-Bromophenyl)diazenyl)piperidine (6) [6h]: 1H
NMR (400 MHz, CDCl3) δ 7.65–7.61 (m, 1H), 7.38–
7.33 (m, 1H), 7.31–7.25 (m, 1H), 7.24–7.18 (m, 1H),
3.86–3.76 (m, 4H), 1.83–1.65 (m, 6H). 13C NMR
(126 MHz, CDCl3) δ 152.5, 130.0, 128.0, 123.0, 123.0,
120.0, 25.5, 24.5.
• 1-((2-Bromophenyl)diazenyl)piperidine (7) [6h]: 1HNMR
(400 MHz, CDCl3) δ 7.60–7.53 (m, 1H), 7.–7.39 (m, 1H),
7.29–7.20 (m, 1H), 7.02–6.94 (m, 1H), 3.98–3.70 (m, 4H),
1.81–1.64 (m, 6H). 13C NMR (126 MHz, CDCl3) δ 148.5,
133.0, 128.0, 126.5, 120.0, 118.5, 25.0, 24.5.
• 2-(Piperidin-1-yldiazenyl)benzoic acid (8): 1H NMR
(500 MHz, CDCl3) δ 13.99 (s, 1H), 8.28–8.22 (m, 1H),
7.72–7.68 (m, 1H), 7.53–7.47 (m, 1H), 7.31–7.25 (m, 1H),
3.98–3.90 (m, 2H), 3.88–3.78 (m, 2H), 1.91–1.74 (m, 6H).
13CNMR (126MHz, CDCl3) δ 167.5, 148.5, 133.5, 132.5,
126.5, 122.0, 116.0, 54.0, 45.5, 26.0, 24.0, 23.5. HRMS
(EI+): [C12H15O2N3] calc. 233.1164, found 233.1162. m.
p. (acetone): 88–89 °C. IR: 2945, 1703, 1704, 1593, 1410,
1109, 766, 692, 608 cm−1.
• 1-(Phenyldiazenyl)piperidine (9) [6h]: 1H NMR (400 MHz,
CDCl3) δ 7.46–7.40 (m, 2H), 7.37–7.30 (m, 2H), 7.19–7.12
(m, 1H), 3.84–3.71 (m, 4H), 1.77–1.64 (m, 6H). HRMS
(EI+): [C11H15N3] calc. 189.1266, found 189.1263.
• 3-(Piperidin-1-yldiazenyl)quinoline (10): 1H NMR
(500 MHz, CDCl3) δ 9.14–9.07 (m, J = 2.2 Hz, 1H),
8.09–8.04 (m, J = 8.8 Hz, 1H), 8.04–7.99 (m, J = 2.2 Hz,
1H), 7.80–7.75 (m, J = 8.5 Hz, 1H), 7.62–7.56 (m, J =
11.3, 4.0 Hz, 1H), 7.51–7.45 (m, J = 7.5 Hz, 1H), 3.94–
3.78 (m, J = 5.5 Hz, 4H), 1.80–1.66 (m, 6H). HRMS
(EI+): [C14H16N4] calc. 240.1375, found 240.1373.
4.3. General Method for the Preparation of Triazenes 11–
15 in Flow (Scheme 6). Solutions of the p-bromoaniline
(0.2 M in acetonitrile), HCl (0.6 M in water), isoamylnitrite
(0.2 M in acetonitrile), and a secondary amine (0.9 M in
acetonitrile) were prepared. These were then pumped through
the flow system (see Scheme 5) at a flow rate of 0.2 mL/min.
After reaching steady state (20 min), 20 mL (1 mmol, 25 min)
was collected. The reaction mixture was neutralized with aque-
ous NaHCO3, extracted with EtOAc (3 × 20 mL), washed with
brine, and dried over MgSO4. After removing the solvent under
reduced pressure, the crude product was taken up in CH2Cl2
and filtered through a plug of silica. If the purity of the product
did not exceed 90%, the crude product was further purified by
column chromatography.
• 1-((4-Bromophenyl)diazenyl)pyrrolidine (11) [19]: 1H
NMR (400 MHz, CDCl3) δ 7.44–7.39 (m, 2H), 7.31–
7.26 (m, 2H), 3.77 (bs, 4H), 2.14–1.88 (m, 4H). 13C
NMR (126 MHz, CDCl3) δ 150.5, 132.0, 122.0, 118.0,
51.0, 46.5, 24.0.
• 4-((4-Bromophenyl)diazenyl)morpholine (12) [20]: 1H
NMR (400 MHz, CDCl3) δ 7.52–7.42 (m, 2H), 7.37–7.28
(m, 2H), 3.89–3.82 (m, 4H), 3.82–3.75 (m, 4H). 13C NMR
(101 MHz, CDCl3) δ 149.0, 132.0, 122.5, 120.0, 66.5.
• 1-(4-Bromophenyl)-3,3-diisopropyltriaz-1-ene (13) [21]:
1H NMR (400 MHz, CDCl3) δ 7.44–7.38 (m, 2H), 7.31–
7.26 (m, 2H), 5.27 (bs, 1H), 3.99 (bs, 1H), 1.30 (bs,
12H). 13C NMR (126 MHz, CDCl3) δ 151.0, 132.0,
122.0, 117.5, 49.0, 46.0, 24.0, 19.5.
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• Methyl(4-bromophenyl)diazenyl)-L-prolinate (14): 1H
NMR (500 MHz, CDCl3) δ 7.45–7.39 (m, 2H), 7.31–
7.25 (m, 2H), 4.66 (bs, 1H), 4.22–3.55 (m, 5H), 2.41–
2.28 (m, 1H), 2.25–1.97 (m, 3H). 13C NMR (126 MHz,
CDCl3) δ 172.5, 140.5, 131.5, 122.5, 119.0, 63.5, 59.5,
52 .5 , 51 .0 , 47 .0 , 29 .0 , 23 .0 . HRMS (EI+) :
[C12H14N3O2Br+H]
+ calc. 312.0348, found 312.0351.
IR: 2951, 2876, 1740, 1479, 1427, 1392, 1323, 1148,
1067, 827 cm−1.
• 1-(4-Bromophenyl)-3,3-dimethyltriaz-1-ene (15): 1H
NMR (400 MHz, CDCl3) δ 7.46–7.40 (m, 1H), 7.33–
7.27 (m, 1H), 3.34 (bs, 3H).13C NMR (126 MHz,
CDCl3) δ 150.0, 132.0, 122.0, 118.50.
4.4. Preparation of Internal Triazenes 16 and 17 in Flow
(Scheme 8)
4.4.1. 1-Phenyl-1H-benzo[d][1,2,3]triazole (16) [22]. Solu-
tions of the N-phenyl-o-phenylenediamine (0.2 M in acetoni-
trile), HCl (0.6 M in water), and isoamylnitrite (0.2 M in
acetonitrile) were prepared. Together with a fourth stream of
acetonitrile, these were then pumped through the flow system
(see Scheme 5) at a flow rate of 0.2 mL/min. After reaching
steady state (20 min), 20 mL (1 mmol, 25 min) was collected.
The reaction solution was neutralized with aqueous NaHCO3,
extracted with EtOAc (3×20 mL), washed with brine, and dried
over MgSO4. After column chromatography (petroleum ether–
DCM), the title compound (16) was obtained as a colorless
solid in 98% yield (0.192 g).
1H NMR (400 MHz, CDCl3) δ 8.18–8.12 (m, 1H), 7.83–7.72
(m, 3H), 7.65–7.58 (m, 2H), 7.58–7.47 (m, 2H), 7.47–7.40 (m,
1H). 13C NMR (101 MHz, CDCl3) δ 146.5, 137.0, 132.5, 130.0,
129.0, 128.5, 124.5, 123.0, 120.5, 110.5.
4.4.2. 3-(2-Chloroethyl)-4-oxo-3,4-dihydroimidazo[5,1 d]
[1,2,3,5] tetrazine-8-carboxamide (17, Mitozolomide) [23]. To
a solution of 5-aminoimidazole-4-carboxamide (0.631 g,
5.0 mmol) in dry acetonitrile (50 mL) at −7 °C, 2-chloroethyl
isocyanate (0.530 g, 1.1 equiv.) in dry acetonitrile (10 mL) was
added dropwise over 1 h.AQ8 The mixture was stirred overnight at
25 °C and quenched with water (10 mL), and the product was
collected and washed successively with water (10 mL) and
ethyl acetate (3×10 mL) to yield 5-amino-N1-(2-chloroethyl)-
1H-imidazole-1,4-dicarboxamide as a white solid (72%,
0.838 g) [24].
1H NMR (400 MHz, DMSO) δ 8.78 (t, J = 5.2 Hz, 1H), 7.65
(s, 1H), 7.03–6.66 (m, J = 36.2 Hz, 2H), 6.39 (s, 2H), 3.76 (t, J
= 6.0 Hz, 2H), 3.60–3.50 (m, J = 5.8 Hz, 2H). 13C NMR
(126 MHz, DMSO) δ 166.5, 150.5, 143.5, 126.0, 111.5, 43.0,
42.0.
Solutions of 5-amino-N1-(2-chloroethyl)-1H-imidazole-1,4-
dicarboxamide (0.2 M) in a mixture of DMSO and acetonitrile
(1:4, v/v), HCl (0.6 M in water), and isoamylnitrite (0.2 M in
acetonitrile) were prepared. Together with a fourth stream of
acetonitrile, these were then pumped through the flow system
(see Scheme 5) at a flow rate of 0.2 mL/min. The product was
extracted with CHCl3 (3×50 mL), washed with brine, and dried
over MgSO4. After removing the solvent under reduced pres-
sure, the crude product was washed with petroleum ether–
diethyl ether (50:50, v/v, 3×10 mL) and dried under reduced
pressure to yield the product as a pale pink solid in 53% yield
(0.128 g, 17).
1H NMR (400 MHz, CDCl3) δ 8.45 (s, 1H), 7.24 (s, 1H),
6.03 (s, 1H), 4.77 (t, J = 6.0 Hz, 2H), 4.00 (t, J = 6.0 Hz, 2H).
13C NMR (101 MHz, CDCl3) δ 161.5, 139.0, 134.0, 132.0,
128.5, 50.5, 41.0.
4.5. Method for the Preparation of 5-(3,3-Dimethyltriaz-
1-en-1-yl)-1H-imidazole-4-carboxamide (Decarbazine)
[25].AQ9 Solutions of 5-amino-1H-imidazole-4-carboxamide
(0.2 M) in a mixture of aqueous HCl (0.6 M) and acetonitrile
(3.5:6.5, v/v), HCl (0.6 M in water), and isoamylnitrite (0.2 M in
acetonitrile) were prepared. Together with a fourth stream of
acetonitrile, these were then pumped through the flow system
(see Scheme 5) at a flow rate of 0.2 mL/min. After reaching
steady state (20 min), 20 mL (1 mmol, 25 min) was collected.
The product was extracted with CHCl3 (3 × 50 mL), washed
with brine, and dried over MgSO4. After removing the solvent
under reduced pressure, the crude product was washed with
petroleum ether–diethyl ether (50:50, v/v, 3×10 mL) and dried
under reduced pressure to yield the product as a pale yellow
solid in 47% yield (0.855 g).
1H NMR (400 MHz, CDCl3) δ 7.59 (s, 1H), 6.91 (bs, 1H),
5.58 (bs, 1H), 2.17 (s, 6H). IR: 3279, 2193, 1709, 1524, 1449,
1371, 1343, 1261 cm−1. HRMS (AP+): C6H10N6O+Na]
+ calc.
205.0814, found 205.0796.
4.6. Large-Scale Experiment. AQ10Solutions of 4-bromoaniline
(0.2 M in acetonitrile), HCl (0.6 M in water), isoamylnitrite
(0.2 M in acetonitrile), and piperidine (0.9 M in acetonitrile)
were prepared. These were then pumped through the flow
system (see Scheme 9) at a flow rate of 0.2 mL/min. After
reaching steady state (20 min), the reaction was run for 18 h.
The first 50 mL (2.5 mmol, 62.5 min) was collected. The
reaction solution was neutralized with aqueous NaHCO3,
extracted with EtOAc, washed with brine, and dried over
MgSO4. After removing the solvent under reduced pressure,
the crude product was taken up in CH2Cl2 and filtered through a
plug of silica to yield the clean compound 5 (92%, 0.587 g,
2.3 mmol).
Acknowledgments. We thank the Bolashak International
Scholarship of the President of the Republic of Kazakhstan
(YS), Cardiff University, and the Royal Society (DLB, award
number RG150376) for financial support and EPSRC UK
National Mass Spectrometry Facility at Swansea University
for MS measurements. The authors are grateful to Prof. Kenneth
D. M. Harris and Dr. Colan Hughes for support in obtaining the
DSC results.
Supporting Information
Electronic Supplementary Material (ESM), including com-
pound characterization and copies of NMR spectra, is available
in the online version at doi: 10.1556/1846.2016.00025.
References
1. AQ11(a) Mo, F.; Dong, G.; Zhang, Y.; Wang, J. Org. Biomol. Chem. 2013, 11,
1582; (b) Kölmel, D. K.; Jung, N.; Bräse, S. Aust. J. Chem. 2014, 67, 328; (c)
Roglans, A.; Pla-Quintana, A.; Moreno-Mañas, M. Chem. Rev. 2006, 106, 4622;
(d) Felpin, F.-X.; Nassar-Hardy, L.; Le Callonnec, F.; Fouquet, E. Tetrahedron
2011, 67, 2815; (e) Taylor, J. G.; Moro, A. V.; Correia, C. R. D. Eur. J. Org.
Chem. 2011, 1403.
2. (a) Mich, T. F.; Nienhouse, E. J.; Farina, T. E.; Tufariello, J. J. J. Chem. Ed.
1968, 45, 272; (b) Sheng, M.; Frurip, D.; Gorman, D. J. Loss Prevent. Proc.
2015, 38, 114.
3. For reviews on continuous-flow processing of diazonium salts and diazo
compounds, see: (a) Deadman, B. J.; Collins, S. G.; Maguire, A. R. Chem. Eur. J.
2015, 21, 2298; (b) Müller, S. T. R.; Smith, D.; Hellier, P.; Wirth, T. Synlett 2014,
25, 871; (c) Oger, N.; Le Grognec, E.; Felpin, F.-X. Org. Chem. Front. 2015, 2,
590–614.
4. For some research articles concerning diazonium salts and diazo com-
pounds in flow, see: (a) Poh, J. S.; Browne, D. L.; Ley, S. V. React. Chem. Eng.
2016, 1, 101–105; (b) Pieber, B.; Kappe, Org. Lett. 2016, 18, 1076–1079; (c)
Browne, D. L.; Baxendale, I. R.; Ley, S. V. Tetrahedron 2011, 67, 10296–10303;
(d) Poh, J. S.; Tran, D. N.; Battilocchio, C.; Hawkins, J. M.; Ley, S. V. Angew.
Chem., Int. Ed. 2015, 54, 7920–7923; (e) Roda-Monsalvez, N. M.; Tran, D. N.;
Battilocchio, C.; Labes, R.; Ingham, R. J.; Hawkins, J. M.; Ley, S. V. Org.
Biomol. Chem. 2015, 13, 2550–2554; (f) Tran, D. N.; Battilocchio, C.; Lou, S.;
Hawkins, J. M.; Ley, S. V. Chem. Sci. 2015, 6, 1120–1125; (g) Martin, L. J.;
Marzinzik, A. L.; Ley, S. V.; Baxendale, I. R. Org. Lett. 2011, 13, 320–323; (h)
Müller, S. T. R.; Murat, A.; Hellier, P.; Wirth, T. Org. Process Res. Dev. 2016, 20,
495–502; (i) Müller, S. T. R.; Smith, D.; Hellier, P.; Wirth, T. Synlett 2014, 25,
871–875; (j) Deadman, B. J.; O'Mahony, R. M.; Lynch, D.; Crowley, D. C.;
Collins, S. G.; Maguire, A. R. Org. Biomol. Chem. 2016, 14, 3423–3431; (k)
Pieber, B.; Kappe, C. O. Org. Lett. 2016, 18, 1076–1079; (l) Garbarino, S.;
Protected Diazonium Salts
Guerra, J.; Poechlauer, P.; Gutmann, B.; Kappe, C. O. J. Flow Chem. 2016, 6, in
press; (m) Nikolaev, V. A.; Cantillo, D.; Kappe, C. O.; Medvedev, J. J.; Prakash,
G. K. S.; Supurgibekov, M. S. Chem. Eur. J. 2016, 22, 174–184; (n) Cantillo, D.;
Mateos, C.; Rincon, J. A.; de Frutos, O.; Kappe, C. O. Chem. Eur. J. 2015, 21,
12894–12898.
5. (a) Lazny, R.; Sienkiewicz, M.; Bräse, S. Tetrahedron 2001, 57, 5825–
5832; (b) Kimball, D. B.; Haley, M. M. Angew. Chem., Int. Ed. 2002, 41, 3338–
3351; (c) May, C.; Moody, C. J. J. Chem. Soc. 1988, 2, 247–250; (d) Vaughan, K.
Org. Prep. Proc. Int. 2001, 33, 59–74.
6. (a) Liu, C.-Y.; Knochel, P. J. Org. Chem. 2007, 72, 7106–7115; (b) Goe-
minne, A.; Scammells, P. J.; Devine, S.M.; Flynn, B. L. Tetrahedron Lett. 2010, 51,
6882–6885; (c) Saeki, T.; Matsunaga, T.; Son, E.-C.; Tamao, K. Adv. Synth. Catal.
2004, 346, 1689–1692; (d) Saeki, T.; Son, E.-C.; Tamao, K.Org. Let. 2004, 6, 617–
619; (e) Bräse, S.; Schroen, M. Angew. Chem., Int. Ed. 1999, 38, 1071–1073; (f)
Barbero, M.; Degani, I.; Diulgheroff, N.; Dughera, S.; Fochi, R. Synthesis 2001, 14,
2180–2190; (g) Döbele, M.; Vanderheiden, S.; Jung, N.; Bräse, S. Angew. Chem.,
Int. Ed. 2010, 49, 5986–5988; (h) Wang, C.; Chen, H.; Wang, Zh.; Chen, J.; Huang,
Y. Angew. Chem., Int. Ed. 2012, 51, 7242–7245; (i) Sun, H.; Wang, C.; Yang, Y.-F.;
Chen, P.;Wu,Y.-D.; Zhang, X. J. Org. Chem. 2014, 79, 11863–11872; (j) Lazny, R.;
Poplawski, J.; Kobberling, J.; Enders, D.; Bräse, S. Synlett 1999, 8, 1304–1306; (k)
Liu, C.-Y.; Knochel, P.Org. Let. 2005, 7, 2543–2546; (l) Lormann,M.; Dahmen, S.;
Bräse, S. Tetrahedron Lett. 2000, 41, 3813–3816; (m) Satyamurthy, N.; Barrio, J.
R.; Bida, G. T.; Phelps, M. E. Tetrahedron Lett. 1990, 31, 4409–4412; (n) Hudson,
J. L.; Jian, H.; Leonard, A. D.; Stephenson, J. J.; Tour, J. M.Chem. Mater. 2006, 18,
2766–2770; (o) Gross, M. L.; Blank, D. H.; Welch, W. M. J. Org. Chem. 1993, 58,
2104–2109; (p) Patrick, T. B.; Juehne, T.; Reeb, E.; Hennessy, D. Tetrahedron Lett.
2001, 42, 3553–3354.
7. (a) Reisman, S. E.; Ready, J. M.; Weiss, M. M.; Hasuoka, A.; Hirata, M.;
Tamaki, K.; Smith, C. J.; Wood, J. L. J. Am. Chem. Soc. 2008, 130, 2087–2100;
(b) Hafner, A.; Bräse, S. Angew. Chem., Int. Ed. 2012, 51, 3713–3715; (c) Wang,
C.; Chen, H.; Wang, Zh.; Chen, J.; Huang, Y. Angew. Chem., Int. Ed. 2012, 51,
7242–7245; (d) Hafner, A.; Feuerstein, T. J.; Bräse, S. Org. Let. 2013, 15, 3468–
3471; (e) Hafner, A.; Bihlmeier, A.; Nieger, M.; Klopper, W.; Bräse, S. J. Org.
Chem. 2013, 78, 7938–7948.
8. (a) Zhang, F.; Spring, D. R. Chem. Soc. Rev. 2014, 43, 6906–6919; (b)
Wang, C.; Huang, Y. Synlett 2013, 24, 145–149.
9. For some reviews on hazardous flow, see: (a) Gutmann, B.; Cantillo, D.;
Kappe, C. O. Angew. Chem., Int. Ed. 2015, 54, 6688–6728; (b) Kulkarni, A. A.
Beilstein J. Org. Chem. 2014, 10, 405–424; (c) Yoshida, J.-I.; Takahashi, Y.;
Nagaki, A. Chem. Commun. 2013, 49, 9896; (d) Gutmann, B.; Kappe, C. O.
Chim. Oggi Chem. Today 2015, 33, 3.
10. (a) Hartwig, J.; Ceylan, S.; Kupracz, L.; Coutable, L.; Kirschning, A.
Angew. Chem., Int. Ed. 2013, 52, 9813; (b) Ghislieri, D.; Gilmore, K.; Seeberger,
P. H. Angew. Chem., Int. Ed. 2015, 54, 678; (c) Newton, S.; Carter, C. F.;
Pearson, C. M.; Alves, L. de C.; Lange, H.; Thansandote, P.; Ley, S. V. Angew.
Chem., Int. Ed. 2014, 53, 4915; (d) Kupracz, L.; A. Kirschning Adv. Synth. Catal.
2013, 355, 3375; (e) Pastre, J. C.; Browne, D. L.; O'Brien, M.; Ley, S. V. Org.
Process Res. Dev. 2013, 17, 1183; (f) Murray, P. R. D.; Browne, D. L.; Pastre, J.
C.; Butters, C.; Guthri, D.; Ley, S. V. Org. Process Res. Dev. 2013, 17, 1192; (g)
Battilocchio, C.; Baxendale, I. R.; Biava, M.; Kitching, M. O.; Ley, S. V. Org.
Process Res. Dev. 2012, 16, 798; (h) Kabeshov, M. A.; Musio, B.; Murray, P. R.
D.; Browne, D. L.; Ley, S. V. Org. Lett. 2014, 16, 4618; (i) Lau, S.-H.; Galván,
A.; Merchant, R. R.; Battilocchio, C.; Souto, J. A.; Berry, M. B.; Ley, S. V. Org.
Lett. 2015, 17, 3218; (j) Correia, C. A.; Gilmore, K.; McQuade, D. T.; Seeberger,
P. H. Angew. Chem., Int. Ed. 2015, 54, 4945; (k) Tsubogo, T.; Oyamada, H.;
Kobayash, S. Nature 2015, 520, 329; (l) Adamo, A.; Beingessner, R. L.;
Behnam, M.; Chen, J.; Jamison, T. F.; Jensen, K. F.; Monbaliu, J.-C. M.;
Myerson, A. S.; Revalor, E. M.; Snead, D. R.; Stelzer, T.; Weeranoppanant,
N.; Wong, S. Y.; Zhang, P. Science 2016, 352, 61–67.
11. For handling solids in flow, see: (a) Deadman, B. J.; Browne, D. L.;
Baxendale, I. R.; Ley, S. V. Chem. Eng. Technol. 2015, 38, 259–264; (b) Browne,
D. L.; Deadman, B. J.; Ashe, R.; Baxendale, I. R.; Ley, S. V. Org. Proc. Res. Dev.
2011, 15, 693–697; (c) Hartman, R. L. Org. Process Res. Dev. 2012, 16, 870–
887; (d) Sedelmeier, J.; Ley, S. V.; Baxendale, I. R.; Baumann, M. Org. Lett.
2010, 12, 3618–3621; (e) Kelly, C. B.; Lee, C. X.; Leadbeater, N. E. Tetrahedron
Lett. 2011, 52, 263–265; (f) Noel, T.; Naber, J. R.; Hartman, R. L.; McMullen, J.
P.; Jensen, K. F.; Buchwald, S. L. Chem. Sci. 2011, 2, 287–290.
12. 19th WHO Model List of Essential Medicines (April 2015). http://www.
who.int/medicines/publications/essentialmedicines/EML2015_8-May-15.pdf
(accessed May 19, 2016).
13. Xicoy, B.; Ribera, J-M.; Miralles, P.; Berenguer, J.; Rubio, R.; Mahillo,
B.; Valencia. M-E.; Abella, E.; López-Guillermo, A.; Sureda, A.; Morgades, M.;
Navarro, J-T.; Esteban, H. Haematologica 2007, 92, 191–198.
14. (a) Zarei, A.; Khazdooz, L.; Aghaei, H.; Azizi, G.; Chermahini, A. N.;
Hajipour, A. R. Dyes Pig. 2014, 101, 295–302; (b) Lunazzi, L.; Cerioni, G.;
Foresti, E.; Macciantelli, D. J. Chem. Soc. Perkin Trans. 2 1978, 7, 686–691.
15. Chen, M.; Buchwald, S. L. Angew. Chem., Int. Ed. 2013, 52, 4247.
16. Clark, A. S.; Deans, B.; Stevens, M. F. G.; Tisdale, M. J.; Wheelhouse, R.
T.; Denny, B. J.; Hartley, J. A. J. Med. Chem. 1995, 38, 1493–1504.
17. For examples of continuous process incorporating inline liquid–liquid
extraction, see: (a) Hornung, C. H.; Mackley, M. R.; Baxendale, I. R.; Ley, S. V.
Org. Proc. Res. Dev. 2007, 11, 399–405; (b) O'Brien, M.; Koos, P.; Browne, D. L.;
Ley, S. V. Org. Biomol. Chem. 2012, 10, 7031–7036; (c) Hu, D. X.; O'Brien, M.;
Ley, S. V.Org. Lett. 2012, 14, 4246–4249; (d) Newby, J. A.; Huck, L.; Blaylock, D.
W.; Witt, P. M.; Ley, S. V.; Browne, D. L. Chem. Eur. J. 2014, 20, 263–271; (e)
Battilocchio, C.; Deadman, B. J.; Nikbin, N.; Kitching,M.O.; Baxendale, I. R.; Ley,
S. V.Chem. Eur. J. 2013, 19, 7917–7930; (f) Snead, D. R.; Jamison, T. F.Chem. Sci.
2013, 4, 2822; (g) Mascia, S.; Heider, P. L.; Zhang, H.; Lakerveld, R.; Benyahia, B.;
Barton, P. I.; Braatz, R. D.; Cooney, C. L.; Evans, J.M. B.; Jamison, T. F.; Jensen, K.
F.; Myerson, A. S.; Trout, B. L. Angew. Chem., Int. Ed. 2013, 52, 12359; (h)
Hartwig, J.; Ceylan, S.; Kupracz, L.; Coutable, L.; Kirschning, A. Angew. Chem.,
Int. Ed. 2013, 52, 9813; (i) Pieber, B.; Martinez, S. T.; Cantillo, D.; Kappe, C. O.
Angew. Chem., Int. Ed. 2013, 52, 10241; (j) Gilmore, K.; Kopetzki, D.; Lee, J. W.;
Horvath, Z.; McQuade, D. T.; Seidel-Morgenstern, A.; Seeberger, P. H. Chem. Eur.
J. 2013, 19, 5450; (k) Kurt, S. K.; Gürsel, I. V.; Hessel, V.; Nigam, K. D. P.;
Kockmann, N. Chem. Eng. J. 2016, 284, 764–777.
18. Li, W.; Beller, M.; Wu, X-F. Chem. Comm. 2014, 50, 9513–9516.
19. (a) Zhang, Y.; Li, Y.; Zhang, X.; Jiang, X. Chem. Comm. 2015, 51, 941–
944; (b) Gross, M. L.; Blank, D. H.; Welch, W. M. J. Org. Chem. 1993, 58,
2104–2109.
20. Sengupta, S.; Sadhukhan, S. K. Org. Synth. 2002, 79, 52.
21. Hafner, A.; Hussal, C.; Bräse, S. Synthesis 2014, 46, 1448–1454.
22. Kumar, R. K.; Ali, M. A.; Punniyamurthy, T. Org. Lett. 2011, 13, 2102–
2105.
23. (a) Wang, Y.; Lambert, P.; Zhao, L.; Wang, D. Eu. J. Med. Chem. 2002,
37, 323–332; (b) Horspool, K. R.; Stevens, M. F. G.; Newton, C. G.; Lunt, E.;
Walsh, R. J. A.; Pedgrift, B. L.; Baig, G. U.; Lavelle, F.; Fizames, C. J. Med.
Chem. 1990, 33, 1393–1399.
24. Wang, Y.; Lowe, P. R.; Thomson, W. T.; Clark, J.; Stevens, M. F. G.
Chem. Comm. 1997, AQ12363–364.
25. Shealy, Y. F.; Krauth, C. A.; Montgomery, J. A. J. Org. Chem. 1962, 27,
2150–2154.
C. Schotten et al.
